These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 16338422)

  • 1. Antisense strategies for oncogene inactivation.
    Stein CA; Benimetskaya L; Mani S
    Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of apoptosis by G3139 in melanoma cells.
    Benimetskaya L; Lai JC; Khvorova A; Wu S; Miller P; Stein CA
    Ann N Y Acad Sci; 2005 Nov; 1058():235-45. PubMed ID: 16394140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genasense (Genta Inc).
    Banerjee D
    Curr Opin Investig Drugs; 2001 Apr; 2(4):574-80. PubMed ID: 11566020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
    Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.
    Moreira JN; Santos A; Simões S
    Rev Recent Clin Trials; 2006 Sep; 1(3):217-35. PubMed ID: 18473975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
    Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
    Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.
    Orr RM
    Curr Opin Mol Ther; 2001 Jun; 3(3):288-94. PubMed ID: 11497353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
    Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA
    Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
    Kim R; Emi M; Tanabe K; Toge T
    Cancer; 2004 Dec; 101(11):2491-502. PubMed ID: 15503311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of antisense oligonucleotides in oncology.
    Pierga JY; Magdelenat H
    Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
    Tamm I
    Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
    Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Technology evaluation: MG-98, MethylGene.
    Zhang Z
    Curr Opin Mol Ther; 2001 Dec; 3(6):599-604. PubMed ID: 11804276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oblimersen in the treatment of metastatic melanoma.
    Tarhini AA; Kirkwood JM
    Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Applications of antisense oligonucleotides in oncology].
    Pierga JY; Cammilleri S; Benyahia B; Magdelénat H
    Bull Cancer; 1994 Dec; 81(12):1023-42. PubMed ID: 7742591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trials referral resource. Current clinical trials of G3139.
    Tock B; Zwiebel JA; Schoenfeldt M
    Oncology (Williston Park); 2003 Sep; 17(9):1244-6, 1251-3, 1258. PubMed ID: 14569852
    [No Abstract]   [Full Text] [Related]  

  • 20. Progress in antisense therapeutics.
    Crooke ST
    Hematol Pathol; 1995; 9(2):59-72. PubMed ID: 7559256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.